Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 7/2008

01.07.2008 | Editorial

Lifting symptom burden—how far off the ground are we?

verfasst von: Mellar P. Davis, Jordanka Kirkova

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Excerpt

Patients with locally advanced or metastatic cancer present with multiple symptoms. A systematic review of symptoms in incurable cancer identified that 37 symptoms occurred in more than 10%, and five of them (fatigue, pain, lack of energy, weakness, and appetite loss) occurred in more than 50% [1]. Sixty nine percent of medical oncologists reported that patients with advanced incurable cancer constituted a significant part of their practice and for 22%, palliative chemotherapy was given to the majority of their practice [2]. …
Literatur
1.
Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34(1):94–104. JulPubMedCrossRef
2.
Cherny NI, Catane R, European Society of Medical Oncology Taskforce on Palliative and Supportive Care (2003) Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: report on a survey by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Cancer 98(11):2502–2510. Dec 1PubMedCrossRef
3.
Cleeland CS, Reyes-Gibby CC (2002) When is it justified to treat symptoms? Measuring symptom burden. Oncology (Williston Park) 16(9 Suppl 10):64–70. Sep
4.
Boyar M, Raftopoulos H (2005) Supportive care in lung cancer. Hematol Oncol Clin North Am 19(2):369–387. vii, AprPubMedCrossRef
5.
Bukowski R, Cella D, Gondek K, Escudier B, Sorafenib TARGETs Clinical Trial Group (2007) Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30(3):220–227. JunPubMedCrossRef
6.
Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T et al (2004) The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 13(1):137–154. FebPubMedCrossRef
7.
Miaskowski C, Lee KA (1999) Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage 17(5):320–332. MayPubMedCrossRef
8.
Cleeland CS (2007) Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 37:16–21. 2(37):16–21PubMedCrossRef
9.
Kirkova J, Walsh D (2007) (Sep) Cancer symptom clusters—a dynamic construct. Support Care Cancer 15(9):1011–1013PubMedCrossRef
10.
Gapstur RL (2007) Symptom burden: a concept analysis and implications for oncology nurses. Oncol Nurs Forum 34(3):673–680. MayPubMedCrossRef
11.
Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ et al (2004) A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11(5):279–292PubMedCrossRef
12.
Servaes P, Verhagen C, Bleijenberg G (2002) Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 38(1):27–43. JanPubMedCrossRef
13.
Visser MR, Smets EM, Sprangers MA, de Haes HJ (2000) How response shift may affect the measurement of change in fatigue. J Pain Symptom Manage 20(1):12–18. JulPubMedCrossRef
14.
Gondek K, Sagnier PP, Gilchrist K, Woolley JM (2007) Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. J Clin Oncol 25(32):5087–5093. Nov 10PubMedCrossRef
15.
Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR (2007) Pharmacologic treatment of cancer-related fatigue. Oncologist 12(Suppl 1):43–51PubMedCrossRef
16.
Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH (2002) Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park) 16(9 Suppl 10):117–124. Sep
17.
Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS (2007) Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 μg every 2 weeks. Cancer 110(7):1629–1640. Oct 1PubMedCrossRef
18.
19.
Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T et al (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7):1021–1030. MayPubMedCrossRef
20.
Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY (2004) Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 58(5):1394–1404. Apr 1PubMedCrossRef
21.
Monk BJ, Huang HQ, Cella D, Long HJ 3rd, Gynecologic Oncology Group Study (2005) Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23(21):4617–4625. Jul 20PubMedCrossRef
22.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413. JunPubMed
23.
Parliament MB, Danjoux CE, Clayton T (1985) Is cancer treatment toxicity accurately reported. Int J Radiat Oncol Biol Phys 11(3):603–608. MarPubMed
24.
Varricchio CG, Sloan JA (2002) The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. J Natl Cancer Inst 94(16):1184–1185. Aug 21PubMed
25.
Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA (2007) A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 109(4):787–795. Feb 15PubMedCrossRef
26.
Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R et al (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23(10):2145–2154. Apr 1PubMedCrossRef
27.
Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D et al (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25(34):5374–5380. Dec 1PubMedCrossRef
28.
Barnes EA, Bruera E (2002) Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 12(5):424–428. Sep–OctPubMedCrossRef
29.
Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G et al (2007) Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin.Oncol 25(32):5070–5077. Nov 10PubMedCrossRef
30.
Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118(8):622–629. Apr 15PubMed
31.
Lai JS, Cella D, Chang CH, Bode RK, Heinemann AW (2003) Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res 12(5):485–501. AugPubMedCrossRef
32.
Yost KJ, Eton DT (2005) Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 28(2):172–191. JunPubMedCrossRef
33.
Dahele M, Skipworth RJ, Wall L, Voss A, Preston T, Fearon KC (2007) Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage 33(6):676–685. JunPubMedCrossRef
34.
Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23(12):2606–2617. Apr 20PubMedCrossRef
35.
Osoba D (1999) What has been learned from measuring health-related quality of life in clinical oncology? Eur J Cancer 35(11):1565–1570. OctPubMedCrossRef
36.
Dooms CA, Pat KE, Vansteenkiste JF (2006) The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. Expert Rev Anticancer Ther 6(4):531–544. AprPubMedCrossRef
37.
Marsh S (2007) Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther 11(2):79–82PubMed
38.
Chada S, Menander KB, Bocangel D, Roth JA, Ramesh R (2008) Cancer targeting using tumor suppressor genes. Front Biosci 13:1959–1967. Jan 1PubMedCrossRef
39.
Fallowfield LJ, Harper P (2005) Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 48(3):365–377. JunPubMedCrossRef
40.
Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317(7161):771–775. Sep 19PubMed
41.
Hassan I, Cima RC, Sloan JA (2006) Assessment of quality of life outcomes in the treatment of advanced colorectal malignancies. Gastroenterol.Clin.North Am 35(1):53–64. MarPubMedCrossRef
42.
43.
Nelson KA, Walsh D (2003) The business of palliative medicine—Part 3: The development of a palliative medicine program in an academic medical center. Am J Hosp Palliat Care 20(5):345–352. Sep–OctPubMedCrossRef
44.
Strasser F, Sweeney C, Willey J, Benisch-Tolley S, Palmer JL, Bruera E (2004) Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage. 27(6):481–491. JunPubMedCrossRef
45.
Homsi J, Walsh D, Nelson KA, LeGrand SB, Davis M, Khawam E et al (2002) The impact of a palliative medicine consultation service in medical oncology. Support. Care Cancer 10(4):337–342. MayPubMedCrossRef
46.
Walsh D, Zhukovsky DS (2004) Communication in palliative medicine: a pilot study of a problem list to capture complex medical information. Am J Hosp Palliat Care 21(5):365–371. Sep–Oct.PubMedCrossRef
47.
Jansman FG, Postma MJ, Brouwers JR (2007) Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 25(7):537–562PubMedCrossRef
48.
Garcia SF, Cella D, Clauser SB, Flynn KE, Lai JS, Reeve BB et al (2007) Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 25(32):5106–5112. Nov 10PubMedCrossRef
Metadaten
Titel
Lifting symptom burden—how far off the ground are we?
verfasst von
Mellar P. Davis
Jordanka Kirkova
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0401-1

Weitere Artikel der Ausgabe 7/2008

Supportive Care in Cancer 7/2008 Zur Ausgabe

Speial Article

When morphine does not work

Original Article

Benchmarking: a useful tool for informing and improving care of the dying?

Original Article

Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study

Original Article

Dying cancer patients’ experiences of powerlessness and helplessness

Erratum

When morphine does not work

Review Article

Prophylaxis of catheter-related venous thrombosis in cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise